Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2016
Price : $35 *
At a glance
- Drugs Immune globulin (Primary)
- Indications Anterior uveitis; Corneal disorders; Ocular inflammation; Pemphigoid
- Focus Therapeutic Use
- 03 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 05 Oct 2015 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017, as reported by ClinicalTrials.gov.
- 05 Oct 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2017, as reported by ClinicalTrials.gov.